Adiponectin serum levels and ADIPOQ (rs2241766) polymorphism in alopecia areata Egyptian patients. 2024

Azza Gaber Antar Farag, and Eman Abd-Elfatah Badr, and Banan Mohamed Gamal Abd-Elaty, and Nada Farag Elnaidany, and Mai Medhat Mohamed Ghanem
Dermatology, Andrology and STDs Department, Faculty of Medicine, Menoufia University, Shebin El-Kom, Menoufia, Egypt.

BACKGROUND Alopecia Areata (AA) is an acquired autoimmune form of non-scarring hair loss. Adiponectin and its gene polymorphism were related to many autoimmune disorders. OBJECTIVE Assessment of adiponectin serum levels and adiponectin gene (ADIPOQ) (rs2241766) Single Nucleoid Polymorphism (SNP) in AA patients and correlating the results with the disease severity in those patients. METHODS This study included 75 AA patients and 75 age and gender-matched healthy subjects (controls). The severity of Alopecia Tool (SALT) score assessment to evaluate AA severity was done. Adiponectin serum levels by ELISA and ADIPOQ (rs2241766) SNP using PCR were performed. RESULTS Adiponectin serum levels were significantly lower in AA patients than controls (p = 0.001). ADIPOQ (rs2241766) TG genotype and G allele were significantly predominant in AA patients increasing its risk by 5 and 4 folds (OR = 5.17, p = 0.001), (OR = 3.82, p = 0.001) respectively. Serum adiponectin levels were negatively correlated with SALT score (r = -0.435, p = 0.001) and associated with alopecia totalis (p = 0.016). ADIPOQ (rs2241766) TG genotype was significantly associated with low serum adiponectin levels and higher SALT score (p = 0.001). CONCLUSIONS The small sample size. CONCLUSIONS ADIPOQ (rs2241766) gene polymorphism (TG genotype and G allele) may modulate AA risk and contribute to the development of AA in Egyptian populations. Decreased circulating adiponectin levels may have a dynamic role in AA etiopathogenesis. Adiponectin serum concentration can be considered a severity marker of hair loss in AA.

UI MeSH Term Description Entries

Related Publications

Azza Gaber Antar Farag, and Eman Abd-Elfatah Badr, and Banan Mohamed Gamal Abd-Elaty, and Nada Farag Elnaidany, and Mai Medhat Mohamed Ghanem
May 2014, European journal of clinical investigation,
Azza Gaber Antar Farag, and Eman Abd-Elfatah Badr, and Banan Mohamed Gamal Abd-Elaty, and Nada Farag Elnaidany, and Mai Medhat Mohamed Ghanem
January 2023, Journal of cancer research and therapeutics,
Azza Gaber Antar Farag, and Eman Abd-Elfatah Badr, and Banan Mohamed Gamal Abd-Elaty, and Nada Farag Elnaidany, and Mai Medhat Mohamed Ghanem
January 2014, PloS one,
Azza Gaber Antar Farag, and Eman Abd-Elfatah Badr, and Banan Mohamed Gamal Abd-Elaty, and Nada Farag Elnaidany, and Mai Medhat Mohamed Ghanem
December 2022, Journal of applied biomedicine,
Azza Gaber Antar Farag, and Eman Abd-Elfatah Badr, and Banan Mohamed Gamal Abd-Elaty, and Nada Farag Elnaidany, and Mai Medhat Mohamed Ghanem
January 2020, Journal of diabetes research,
Azza Gaber Antar Farag, and Eman Abd-Elfatah Badr, and Banan Mohamed Gamal Abd-Elaty, and Nada Farag Elnaidany, and Mai Medhat Mohamed Ghanem
February 2013, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Azza Gaber Antar Farag, and Eman Abd-Elfatah Badr, and Banan Mohamed Gamal Abd-Elaty, and Nada Farag Elnaidany, and Mai Medhat Mohamed Ghanem
June 2008, Journal of dermatological science,
Azza Gaber Antar Farag, and Eman Abd-Elfatah Badr, and Banan Mohamed Gamal Abd-Elaty, and Nada Farag Elnaidany, and Mai Medhat Mohamed Ghanem
January 2014, Indian journal of dermatology,
Azza Gaber Antar Farag, and Eman Abd-Elfatah Badr, and Banan Mohamed Gamal Abd-Elaty, and Nada Farag Elnaidany, and Mai Medhat Mohamed Ghanem
July 2013, Gene,
Azza Gaber Antar Farag, and Eman Abd-Elfatah Badr, and Banan Mohamed Gamal Abd-Elaty, and Nada Farag Elnaidany, and Mai Medhat Mohamed Ghanem
November 2022, Journal of immunoassay & immunochemistry,
Copied contents to your clipboard!